Submit to Special Issue Submit Abstract to Special Issue Review for JPM Edit a Special Issue

Journal Menu

Journal Browser

Special Issue "Precision Medicine Approach in Prostate Cancer"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 20 October 2023 | Viewed by 2222

Share This Special Issue

Special Issue Editor

Dr. Fahad Quhal

E-Mail Website
Guest Editor

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
Interests: prostate cancer; advanced prostate cancer; urothelial cancer

Special Issue Information

Dear Colleagues,

Despite the recent advances in the management of prostate cancer, advanced prostate cancer remains a lethal disease—the heterogeneity of the disease results in significant variability in outcomes across patients. Substantial efforts are ongoing to identify patients who would benefit from certain treatment strategies more than others. Precision medicine allows sub-classifying patients based on biomarkers, disease features, or genomics, allowing individualized treatment approaches to achieve maximum benefit.

This Special Issue of Journal of Personalized Medicine aims to focus on research on the recent advances and future directions in precision medicine approaches in prostate cancer surgery. We invite researchers to address either one of the following topics or a related topic:

Advances in the genomic classification of prostate cancer;
Tissue- and fluid-based biomarkers in prostate cancer;
Novel imaging modalities in evaluating and staging prostate cancer;
Future directions of precision medicine in prostate cancer.

Dr. Fahad Quhal
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

prostate cancer
oncologic outcomes
novel imaging
genomic sequencing
biomarkers
molecular profiling

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer

Wojciech A. Cieślikowski

Catherine Alix-Panabières

Maciej Zabel

Andrzej Antczak

and

Joanna Budna-Tukan

J. Pers. Med. 2023, 13(4), 608; https://doi.org/10.3390/jpm13040608 - 30 Mar 2023

Viewed by 652

Abstract

The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch^® system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56–74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch^® system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter. Full article

(This article belongs to the Special Issue Precision Medicine Approach in Prostate Cancer)

► Show Figures

Figure 1

Open AccessArticle

The Severity of Pain in Prostate Biopsy Depends on the Biopsy Sector

and

J. Pers. Med. 2023, 13(3), 431; https://doi.org/10.3390/jpm13030431 - 27 Feb 2023

Viewed by 644

Abstract

BACKGROUND: The pain experienced by a patient during a prostate fusion biopsy is cumulative and can also be modulated by many factors. The aim of the study was to assess the association between the degree of pain intensity during prostate biopsy and the region of the biopted organ. MATERIALS AND METHODS: The study included a group of 143 patients who underwent prostate fusion biopsy under local analgesia followed by blockage of the periprostatic nerve. After a biopsy, the patients completed the original questionnaire about the pain experienced during the procedure. RESULTS: There was a statistically significant difference in pain score between cores taken in the apex (median 5 (IQR 2–5)), medium level (median 1 (IQR 1–2)), and prostate base (median 1 (IQR 1–3)) (p < 0.001). The malignancy scale ISUP ≥ 2 (p = 0.038) and lower PSA value (r = −0.17; p = 0.046) are associated with higher pain during procedure. Biopsy time was correlated with discomfort (r = 0.19; p = 0.04). Age (p = 0.65), lesion size (p = 0.29), PI-RADS score (p = 0.86), prostate volume (p = 0.22), and the number of cores (p = 0.56) did not correspond to the pain scale. CONCLUSIONS: The apex is the most sensitive sector of the prostate. ISUP ≥ 2 and patients with low PSA levels more often indicated higher values on the pain rating scale. Full article

(This article belongs to the Special Issue Precision Medicine Approach in Prostate Cancer)

► Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review

Pierre I. Karakiewicz

Takahiro Kimura

and

Shahrokh F. Shariat

J. Pers. Med. 2023, 13(4), 641; https://doi.org/10.3390/jpm13040641 - 07 Apr 2023

Viewed by 582

Abstract

(1) Background: Several phase II studies, including randomized controlled trials (RCTs), assessed the efficacy of adding androgen receptor signaling inhibitors (ARSIs) to androgen deprivation therapy (ADT) as a neoadjuvant treatment in patients treated with radical prostatectomy (RP) for prostate cancer (PCa). Summarizing the early results of these studies could help in designing phase III trials and patient counseling. (2) Methods: We queried three databases in January 2023 for studies that included PCa patients treated with neoadjuvant ARSI-based combination therapy before RP. The outcomes of interest were oncologic outcomes and pathologic responses, such as pathologic complete response (pCR) and minimal residual disease (MRD). (3) Results: Overall, twenty studies (eight RCTs) were included in this systematic review. Compared to ADT or ARSI alone, ARSI + ADT was associated with higher pCR and MRD rates; this effect was less evident when adding a second ARSI or chemotherapy. Nevertheless, ARSI + ADT resulted in relatively low pCR rates (0–13%) with a high proportion of ypT3 (48–90%) in the resected specimen. PTEN loss, ERG positive, or intraductal carcinoma seem to be associated with worse pathologic response. One study that adjusted for the effects of possible confounders reported that neoadjuvant ARSI + ADT improved time to biochemical recurrence and metastasis-free survival compared to RP alone. (4) Conclusions: Neoadjuvant ARSI + ADT combination therapy results in improved pathologic response compared to either alone or none in patients with non-metastatic advanced PCa. Ongoing phase III RCTs with long-term oncologic outcomes, as well as biomarker-guided studies, will clarify the indication, oncologic benefits, and adverse events of ARSI + ADT in patients with clinically and biologically aggressive PCa. Full article

(This article belongs to the Special Issue Precision Medicine Approach in Prostate Cancer)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Precision Medicine Approach in Prostate Cancer"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI